Moxifloxacin Ophthalmic Injection Syringes Recalled for Sterility Risk
Edge Pharma is recalling Moxifloxacin sterile ophthalmic injection syringes nationwide due to lack of assurance of sterility. The 860 affected syringes were distributed across two lots.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this as a Class II recall. The hazard—lack of sterility assurance in a preservative-free intraocular injectable—presents significant risk of serious harm (infection, vision loss) to patients undergoing eye injection procedures, even though no illnesses or injuries are reported in the source text.
Plain-English summary
Edge Pharma, LLC is recalling Moxifloxacin, Sterile Ophthalmic Solution for Injection, Preservative Free, 0.8mg/0.8 mL (1mg/mL), 0.8 mL per syringe, Single Use Syringe, For Intraocular Injection (NDC 05446-1050-01) due to lack of assurance of sterility.
The recall affects 860 syringes distributed nationwide. The affected product was manufactured in two lots: 08-2021-26@2 dated 12/09/2021 and 09-2021-23@1 dated 01/05/2022.
Patients and healthcare providers who received this product should discontinue use. Those with questions about whether they received affected product should contact Edge Pharma, LLC at 856 Hercules Dr., Colchester, VT 05446, or refer to the FDA's official recall notice.
The recalled product
- Product
- Moxifloxacin, Sterile Ophthalmic Solution for Injection, Preservative Free, 0.8mg/0.8 mL (1mg/mL), 0.8 mL per syringe, Single Use Syringe, For Intraocular Injection, Edge Pharma, LL, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1050-01
- Manufacturer
- Edge Pharma, LLC
- Category
- Drug — Ophthalmic Injection
- Hazard
- sterility-assurance
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- 08-2021-26@2 12/09/2021 & 09-2021-23@1 01/05/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27